Hylase Dessau (Hyaluronidase)

Hylase Dessau, an hyaluronidase enzyme, is employed where enhanced tissue permeability is required.

• Improved drug absorption: Enhances dispersion of co‑administered subcutaneous agents, increasing their bioavailability.
• Subcutaneous fluid administration: Facilitates even distribution of fluids injected subcutaneously, reducing resistance.
• Extravasation management: Promotes rapid breakdown of hyaluronic acid at leak sites, aiding resolution of drug extravasation.

• Hylase Dessau contains hyaluronidase, an enzyme that hydrolyzes hyaluronic acid in the extracellular matrix. By degrading this polysaccharide, the drug reduces tissue viscosity and increases interstitial permeability, allowing co‑administered substances to spread more readily through the injection site and surrounding tissues.

Adverse reactions to Hylase Dessau are generally related to the injection site or hypersensitivity.

Common Side Effects

• Pain at injection site: mild to moderate discomfort.
• Erythema: localized redness.
• Swelling: transient edema.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with respiratory and cardiovascular compromise.
• Serum sickness-like reaction: fever, rash, arthralgia appearing days later.
• Tissue necrosis: localized tissue death at the injection site.

When using Hylase Dessau, several precautions should be observed to ensure safe administration.

• Allergy assessment: verify no known hypersensitivity to hyaluronidase or bee venom.
• Pregnancy and lactation: use only if clearly indicated, as safety data are limited.
• Anticoagulant therapy: monitor for increased bleeding at the injection site.
• Co‑administration with other enzymes: assess potential additive effects on tissue permeability.
• Patient monitoring: observe for signs of hypersensitivity during and after injection.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hylase Dessau may interact with other medicines, primarily by altering their absorption or through hypersensitivity mechanisms.

Major Interactions (Avoid)

• Known hyaluronidase allergy: avoid use in patients with documented hypersensitivity to hyaluronidase or bee venom.
• Concurrent hyaluronidase‑containing products: avoid simultaneous administration to prevent excessive tissue permeability.

Moderate Interactions (Monitor Closely)

• Vasopressors: monitor blood pressure as hyaluronidase may enhance systemic absorption of co‑administered agents.
• Anticoagulants: watch for prolonged bleeding due to increased tissue dispersion.
• Systemic steroids: assess for potential modulation of immune response affecting hypersensitivity risk.